A vaccine has been approved via the FDA's bioterror pathway for the first time. The specific disease or condition the vaccine targets is unclear, with reports mentioning chikungunya and anthrax. The approval process has raised questions about the safety and implications of emergency use authorizations for vaccines and drugs.